The "Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
"Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018" provides an overview of the pipeline landscape for mucopolysaccharidosis disorders, a group of inherited lysosomal storage disorders.
It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for mucopolysaccharidosis I (MPS I) (Hurler syndrome), mucopolysaccharidosis II (MPS II) (Hunter syndrome) and mucopolysaccharidosis III (MPS III) (Sanfilippo syndrome), and features dormant and discontinued products.
Companies operating in the mucopolysaccharidosis disorders pipeline space include ArmaGen, Sangamo and AngioChem.
Scope
Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area? Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
9 Appendix
Companies Mentioned
Abeona Therapeutics Inc AngioChem Inc ArmaGen Inc Axcentua Pharmaceuticals AB BioMarin Pharmaceutical Inc CRISPR Therapeutics Denali Therapeutics Inc Eloxx Pharmaceuticals Inc GC Pharma Immusoft Corp JCR Pharmaceuticals Co Ltd Laboratorios Del Dr Esteve SA Lysogene SAS Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) OPKO Health Inc RegenxBio Inc Sangamo Therapeutics Inc Shire Plc Swedish Orphan Biovitrum AB For more information about this report visit https://www.researchandmarkets.com/research/rl7npv/mucopolysaccharido?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180817005123/en